[1]王金萍,吴秋莲,徐浩.甲状腺功能与血清饥饿素和瘦素水平的相关陛研究[J].国际放射医学核医学杂志,2008,32(4):221-223.
　WANG Jin-Lian,WU Qiu-lion,XU Hao.Association of thyroid function with human serum ghrelin and leptin levels[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):221-223.
点击复制

甲状腺功能与血清饥饿素和瘦素水平的相关陛研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第4期
页码:
221-223
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Association of thyroid function with human serum ghrelin and leptin levels
作者:
王金萍1;  吴秋莲2;  徐浩1
1. 510630 广州, 暨南大学附属第一医院核医学科;
2. 510632 广州, 暨南大学医学院护理系
Author(s):
WANG Jin-Lian1;  WU Qiu-lion2;  XU Hao1
1. Department of Nuclear Medicine, First Affiliated Hospital, Jinan University, Guangzhou 510630, China;
2. Nursing School, Medical college, Jinan University, Guangzhou 510632, China
关键词:
甲状腺功能亢进症; 甲状腺功能减退症; 饥饿索; 瘦素
Keywords:
yperthyroidism; Hypothyroidism; Ghrelin; Leptin
摘要:
目的 观察甲状腺功能亢进症(甲亢)、甲状腺功能减退症(甲减)及正常人血清饥饿素和瘦索水平,并探讨它们与甲状腺功能的关系。方法 采用放射免疫分析法分别检测46例未接受治疗甲亢患者(甲亢A组)、15例131-I治疗有效的甲亢患者(甲亢B组)、21例甲减患者和18例正常对照者血清饥饿素及瘦素水平,同时采用全自动化学发光免疫分析法检测血清游离三碘甲腺原氨酸(FT3)>、游离甲状腺素(FT4)、促甲状腺素TSH)水平。结果 (1)甲亢A组的血清饥饿索水平明显低于甲亢B组(t=3.21,P<0.01)、甲减组(t=3.02,P<0.01)和正常对照组(t=3.39,P<0.01);甲亢B组、甲减组和正常对照组之间的血清饥饿索水平比较无显著差异。(2)甲亢A组血清瘦素水平与甲亢B组、甲减组和正常对照组比较无显著差异;甲亢B组、甲减组和正常对照组之间的血清瘦索水平比较兄显著差异。(3)血清饥饿素水平与血清FT3)(r=-O.29,P<0.05)和FT4)(r=-O.26,P<0.05)呈负相关,与TSH呈正相关(r=0.36,P<0.05);血清瘦素水平与血清FT3)、FT4)和TSH无显著相荚性。结论 血清饥饿素水平在不同甲状腺功能状态下不同,并与甲状腺激素水平有-定的相关性,而血清瘦索无此作用。
Abstract:
Objective To investigate the effect of different status of thyroid function (hypothyroidism and hyperthyroidism as well a8 euthyroid status)on serum ghrelin and leptin levels.Methods The levels of semm ghrelin and leptin were determined by radio immunoassay in 46 untreated subjects with hyperthyroidism.15 hyperthyroid patients achieved aeuthyroid status after radioiodine 131I therapy,21 cases of hypothyroidism and 18 cases of normal controls,respectively.Meanwhile,the serum levels of free triiodothyronine (FT3),free thyroxine (FT4) and thyroid-stimulating hormone (TSH) were measured by chemiluminescence immune assay.Results (1) The levels of serum ghrelin in untreated hyperthyroidism were significantly lower than those in hyperthyroid patients achieved aeuthyroid status (t=3.21,P<0.01). hypothyroidism (t=3.02,P<0.01) and the normal gruups (t=3.39,P<0.01),but the levels of serum ghrelin in hypothyroidism patients were similar to those in normal groups;(2) The levels of sernm leptin did not differ; (3) Serum ghrelin levels were negatively correlated with FT3 (r=-0.29,P<0.05) and,FT4 (r=-0.26,P<0.05),positively correlated with serum TSH (r=0.36,P<0.05);serum leptin levels did not correlate with thyroid hormone.Conclusion The levels of serum ghrelin Welm,differently under different thyroid funotional status and correlated with thyroid hormone,while serum leptin were not.

参考文献/References:

[1] Kamegai J,Tamum H,Shimizu T,et al.The role of pituitary ghrelin in growth hormone (GH) secretion:GH-releasing hormone-dependent regulation of pituitary ghrelin gene expression and peptide content[J].Endocrinology,2004,145(8):3731-3738.
[2] Chan JL,Mantzoros CS.Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa[J].Lancet,2005,366(9479):74-85.
[3] Giménez-Palop O,Giménez-Pérez G,Mauficio D,et al.Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger,food intake or anthropometric changes[J].Eur J Endocrinol,2005,153(1):73-79.
[4] Soriano-Guillén L,Barrios V,Campos-Barros A,et al.Ghrelin levels in obesity and anorexia nervosa:effect of weight reduction or recuperation[J].J Pediatr,2004,144(1):36-42.
[5] Ishii S,Kanegai J,Tamura H,et al.HypothMaIllic neuropeptide Y/YI receptor pathway activated by a reduction in circulating leptin, but not by an increase in circulating ghrelin,contributes to hyperphagia associated with triiodothyronine-induced thyrotoxico-sis[J].Neuroendocrinology,2003,78(6):321-330.
[6] Riis AL Hansen TIC.Moiler N,et al.Hyperthyroidism is associated with suppressed circulating ghrelin level[J].J Clin Endocrinol Metab,2003,88(2):853-857.
[7] Pinkney JH,Goodrick SJ,Katz JR,et al.Thyroid and sympathetic influences on plasma leptin in hypothyroidism and hyperthyroidism[J]. Int J Obes Relat Metab Disord,2000,24(Suppl 2):S165-S166.
[8] 谢克俭,张琦,徐云弟,等.自身免疫性甲状腺炎患者血清瘦素的检测及其与发病的关系啊.中华检验医学杂志.2004,27(2): 100-101.
[9] Yaturn S,Prado S,Grimes SR.Changes in adipocyte hormones leptin,resistin,and adiponectin in thyroid dysfunction[J].J Cell Biochem,2004,93(3):491-496.
[10] 彭扬,田坚,沈静雪,等.初诊甲亢患者血清瘦素质量浓度的观察[J].中国实用内科杂志,2004,24(3):185.[l] Sera N,Kawakami A,Nakashima T.et al.Fas/FasL mediated apoptpsis of thyrecytes in Graves’ disease[J].Clin Exp lmmunol, 2001,124(2):197-207.
[2] Diez JJ,Hemanz A,Mdeina S,et al.Serum concentrations of tumor necrosis factor-alpha TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function[J].Clin Endocfinol (Oxf),2002,57(4):515-521.
[3] Ajmone-Cat MA,De Simone R, Niceolini A,et al.Effects of phosphatidylsefine on p38 mitogen activated protein kinase,cyclic AMP responding element binding protein and nuclear factorkappaB activation in resting and activated microglial cells[J].J Neumchem,2003,84(2):413-416.
[4] Ugnr-Ahun B,Altun A,Arikan E,et al.Relationships existing between the serum cytokine levels and bone mineral density in women in the promenopausal period affected by Graves’ disease with subclinical hyperthyroidism[J].Endocr Res,2003,29(4): 389-398.
[5] Hiromatsu Y,Yang D,Bednarczuk T,et al.Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy[J].J Clin Endocrinol Metab,2000,85(3):1194-1199.
[6] 王爱萍,蒋琳,刘超,等.细胞因子在Graves眼病发病中的作用机理[J].国外医学内分泌学分册,2003,23(6):401-402.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]贾强,孟召伟,谭建.异位甲状腺发病机理、诊断与治疗的研究进展[J].国际放射医学核医学杂志,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
　Jia Qiang,Meng Zhaowei,Tan Jian.Progress of pathogenisis, diagnosis and treatment of ectopic thyroid[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
[4]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[7]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[8]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[9]孟召伟,谭建.美国甲状腺协会和临床内分泌医师协会2012年甲减诊治指南介绍[J].国际放射医学核医学杂志,2013,37(2):124.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hypothyroidism published in 2012 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):124.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
[10]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[11]郭永铁.促甲状腺激素与亚临床性甲状腺功能异常[J].国际放射医学核医学杂志,2008,32(6):351.
　GUO Yong-tie.Thyroid stimulating hormone and subclinical thyroid dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):351.
[12]陈再君,蒋宁一.131I治疗甲亢后致甲减的研究变迁[J].国际放射医学核医学杂志,2004,28(4):153.
　CHEN Zai-jun,JIANG Ning-yi.The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):153.
[13]李诗运.131I治疗甲亢后甲减的综合预防和处理措施[J].国际放射医学核医学杂志,2004,28(4):157.
　LI Shi-yun.Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):157.

备注/Memo

备注/Memo:
收稿日期:2008-02-08。
通讯作者:徐浩,E-mail:txh@jnu.edu.cn
更新日期/Last Update: 1900-01-01